Nilotinib-associated vascular events

Medicine & Life Sciences

• 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 100%
• Blood Vessels 40%
• Imatinib Mesylate 19%
• Peripheral Arterial Disease 19%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18%
• Embolism 8%
• Protein Binding 8%
• Vascular Diseases 8%
• Coronary Artery Disease 7%
• Diabetes Mellitus 6%
• Phosphotransferases 6%
• Stroke 5%
• Clinical Trials 5%
• Safety 5%
• Lung 4%
• Therapeutics 4%
• Incidence 4%
• In Vitro Techniques 3%